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We studied the influence of pretreatment with endothelin–1 on cardiac baroreflexes
and on the effect of clonidine on blood pressure and heart rate. In order to avoid the
complication of the direct vasoconstrictor effects of endothelin-1, initial dose-response
studies in animals treated with a ganglion blocker were performed. Intravenous
administration of 50, 200, and 1200 ng/kg of endothelin-1 produced biphasic changes
in blood pressure, consisting of an immediate depressor response, followed by a long
lasting and dose-dependent pressor effect (peak response 3 ± 1, 9 ± 3, and 33 ± 5
mmHg, respectively). Thus, the 50 ng/kg dose of endothelin-1 was used in subsequent
studies. Conscious rabbits were pretreated on separate days with endothelin-1, either
intravenously (50 ng/kg) or intracisternally (10 and 50 ng/kg), or with vehicle. The
animals then received an intravenous dose (20 µg/kg) or an intracisternal dose (1
µg/kg) of clonidine and the effects on blood pressure and heart rate were measured. In
vehicle-treated rabbits, the intravenous administration of clonidine induced a significant
decrease in blood pressure and heart rate (15 min after injection:−15.7± 4.7 mmHg and
−33 ± 4 b/min, respectively). Similarly, the intracisternal injection of clonidine lowered
blood pressure (−16.0 ± 2.5 mmHg), but produced a less pronounced bradycardia
(−18 ± 4 b/min). Endothelin pretreatment, either 50 ng/kg centrally or peripherally,
had no significant effect on the hypotension or bradycardia produced either by central
or peripheral injection of clonidine. At this dose, endothelin by itself did not produce
significant changes in blood pressure or heart rate. There was a reduction of the gain of
the baroreceptor-heart rate reflex with intracisternal endothelin-1. These results suggest
that central 2–adrenoceptor mechanisms involved in clonidine-induced hypotension and
bradycardia do not appear to be influenced by activation of endothelin receptors.
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INTRODUCTION
Endothelin, an endothelium-derived 21 amino–acid peptide, is a potent vasoconstrictor which
was isolated by Yanagisawa et al. (1988). Three isoforms of endothelin have been characterized:
endothelin-1, endothelin-2, and endothelin-3, which differ in their distribution in the body and
in their effects (Inoue et al., 1989; Sokolovsky, 1992). Intravenous injection of endothelins in
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rats evoked a characteristic biphasic effect on blood pressure,
consisting of an early hypotension followed by a longlasting
increase in blood pressure (Yanagisawa et al., 1988). Local
production of endothelins in the vascular wall may play
an important role in the regulation of blood pressure and
haemodynamic flow and could be involved in the pathogenesis
of cardiovascular disease (Sokolovsky, 1992; Huggins et al., 1993;
Sandoo et al., 2010).
In addition to the systemic circulation, endothelin production
and endothelin receptors have been demonstrated in the central
nervous system. The central administration of endothelins
modulates endocrine and cardiovascular regulation and behavior
(van den Buuse, 1997). For example, endothelins were found to
be involved in the regulation of vasopressin release (Yoshizawa
et al., 1990; Yu et al., 2001) and baroreflex sensitivity (Itoh
and van den Buuse, 1991; Abukar et al., 2016). Furthermore,
injections of endothelins intracisternally or locally into the
rostral ventrolateral medulla produced marked changes in blood
pressure (Kuwaki et al., 1991; Mosqueda-Garcia et al., 1992;
Kumada et al., 2003; Lu et al., 2005).
Clonidine is a clinically used centrally-acting antihypertensive
agent with agonist activity at α2–adrenoceptors and additional
actions at the imidazoline-preferring receptors (Kobinger, 1978;
Ernsberger et al., 1987). It lowers blood pressure through
inhibition of sympathetic vasomotor tone and a reduction of
cardiac output (Badoer et al., 1983). The site of action of clonidine
is most likely in the medulla oblongata (Punnen et al., 1987; Gatti
et al., 1988).
Studies by Gulati and co-workers have led to the suggestion
of an interaction between the effects of endothelin and clonidine
in anaesthetized rats (Gulati, 1992; Gulati and Srimal, 1993).
Intravenous administration of subpressor doses of endothelin
blocked the hypotension and bradycardia produced by clonidine
but did not inhibit the initial hypertensive response. The authors
suggested that endothelin crossed the blood-brain barrier to
block the central hypotensive actions of clonidine, and that
central and peripheral α2–adrenoceptors therefore may be
differentially influenced by endothelin. The pharmacological
interaction between endothelin and clonidine suggested in
these studies is unexpected as these compounds clearly interact
at distinct and dissimilar receptors. The authors examined
this question in urethane-anaesthetized rats and found that
endothelin antagonized the effects of clonidine and that
endothelin antagonists, such as the ETA/B antagonist, TAK-044,
and the ETA antagonist, BMS-182874, potentiated the effects of
clonidine (Lavhale et al., 2010). They also found that clonidine
produced an increase in ETA receptor expression in the brain
and abdominal aorta and concluded that endothelin enhances the
responsiveness of vascular adrenoceptors to the constrictor effect
of clonidine and ET antagonists potentiate the hypotensive effect
of clonidine (Lavhale et al., 2010). One possibility was that this
interaction was a functional rather than a pharmacological one.
Thus, it is important to examine the interaction of endothelin
and clonidine using doses of endothelin that have minimal direct
vascular constrictor effects.
The principle aim of the present study was to investigate the
central and peripheral cardiovascular effects of endothelin and its
interaction with clonidine using a conscious animal preparation.
In this study we used rabbits since the haemodynamic and
cardiovascular reflex effects of clonidine have been very well
characterized in this species (Badoer et al., 1983; Head and Burke,
1991). We examined both the effects of central (intracisternal)
and systemic (intravenous) treatment with endothelin on blood
pressure and heart rate and the interaction of pretreatment
with endothelin on blood pressure responses to intravenous and
intracisternal administration of clonidine. We also examined the
effects of central doses of endothelin on baroreceptor heart rate
reflexes.
MATERIALS AND METHODS
Animals, Operations, and Measurements
All experiments and surgical procedures were approved by the
Baker Medical Research Institute/Alfred Hospital Animal Ethics
Committee and were in accordance with the guidelines of the
National Health and Medical Research Council of Australia.
The experiments were performed in 6 (dose-response studies),
7 (interaction studies), and 9 (baroreflex studies) conscious male
and female rabbits of mixed breed with a body weight ranging
between 2.4 and 3.0 kg.
For the interaction studies, during a preliminary operation
the animals were anaesthetized with halothane (Fluothane,
ICI Australia) after induction with intravenously administered
propofol (Diprivan, ICI Pharmaceuticals, England, 10mg/kg). A
vinyl catheter of 0.28 mm internal diameter and 0.61 mm outer
diameter (SV10, Dural Plastics, Australia) was inserted 8 mm
through the atlanto–occipital membrane such that the tip lay in
the fourth ventricle (Head et al., 1983). The first experiment was
performed approximately 1 week after surgery.
For the barororeflex studies under similar anaesthesia, small
silastic aortic and vena caval balloons were implanted in the
chest of rabbits in two separate operations with at least 2 weeks
recovery in between (Korner et al., 1979).
On the day of the experiment the central ear artery and
marginal ear vein were catheterized transcutaneously with a
25 mm, 22 gauge Teflon catheter (Jelco, intravenous catheter
placement unit, Johnson and Johnson Medical, Australia) and a
23 gauge stainless steel needle catheter, respectively, under local
anaesthesia with 1% prilocaine (Citanest, Astra Pharmaceuticals,
Australia). The end of the intracisternal catheter was retrieved,
using local anaesthesia, from under the skin at the back of the
neck.
Mean arterial pressure (MAP) and heart rate were recorded
on a polygraph (Grass, model 7D). For the MAP measurements,
Statham P23D transducers were used, while heart rate was
measured using a Baker Medical Research Institute rate meter
which was triggered by the pulsatile arterial pressure signal.
The MAP and heart rate signals were digitized with an
analog-to-digital conversion card (Metrabyte DAS-8) and PC
compatible computer. Software developed at the Baker Medical
Research Institute was used to average the data over 20 s
periods for analysis. At least 1 h recovery from the minor
operative procedures was allowed before the experiment was
begun.
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Experimental Protocols
Preliminary experiments were performed to investigate the
pressor action of endothelin-1 in conscious rabbits and to assess
the biological activity of the endothelin-1 used in our studies.
Six rabbits were treated intravenously with a ganglionic blocker
(mecamylamine, 4 mg/kg, or pentolinium, 5 mg/kg) and injected
intravenously with different doses of endothelin-1 (Auspep,
Australia, 50, 200, and 1200 ng/kg) with 10-15 min intervals
between injections.
In the main series of experiments, in which we investigated
the possible interaction of endothelin–1 and clonidine HCl
(Catapres, Boehringer Ingelheim), each of the 7 rabbits was
studied on six separate occasions, with 2–3 days between
experiments. The order of treatments over the six separate
experiments was determined according to a Latin square design.
These consisted of (a) intravenous (n = 3) or intracisternal
(n = 4) pretreatment with vehicle (Ringers Injection Solution)
followed by intravenous injection of 20 µg/kg clonidine, (b)
intravenous pretreatment with 50 ng/kg of endothelin-1 followed
by intravenous clonidine (n = 7), (c) intracisternal pretreatment
with 10 ng/kg of endothelin-1 followed by intravenous clonidine
(n = 7), (d) intracisternal pretreatment with 50 ng/kg of
endothelin-1 followed by intravenous clonidine (n = 7), (e)
intracisternal injection of vehicle followed by intracisternal
injection of 1 µg/kg of clonidine (n = 7), (f) intracisternal
injection of 10 ng/kg of endothelin-1 followed by intracisternal
injection of 1 µg/kg of clonidine (n = 7). In all cases, after
an initial 20 min control period was recorded, the rabbits
received their pretreatment. A 5 min post-treatment control
period was then recorded 30 min after this first injection to
indicate any effect on resting MAP or heart rate followed by the
intravenous or intracisternal injection of clonidine. Changes to
MAP and heart rate were then observed for the next 60 min.
Two-minute digitized recordings were taken at regular intervals
after clonidine administration. The effect of clonidine was taken
during the maximum fall in MAP at 15 min post-injection for
subsequent statistical analysis.
For the baroreflex cuves, 20–30 inflations of the venous cuff
were performed to reduce venous return and hence arterial
pressure or of the aortic cuff to increase aortic and carotid
pressure before and after vehicle or endothelin-1 (2 ng/kg,
10 ng/kg). Each cuff was held for 30 s at a steady state pressure.
Aortic and venous cuffs were alternated to avoid baroreceptor
resetting. The final values (at the end of 30 s) for MAP and HR
were averaged over 2 s intervals and fitted to a sigmoid logistic
function to produce MAP-HR curves. A non-linear regression
program utilized the Marquardt-Levenberg method to fit a five
parameter logistic equation as described previously (Ricketts and
Head, 1999). Parameters included the lower plateau, which was
the minimum HR, the range between the lower plateau and
upper plateau (which was a calculated maximum activation)
and the median blood pressure at half the reflex range (BP50).
Two curvature parameters were used which allowed for a non-
symmetrical fit of the data. The average range-dependent slope
between the two inflection points of the first derivative curve
(gain) was calculated as the average of the curvature parameters
multiplied by the range and divided by 4.562 (Ricketts and Head,
1999).
Both endothelin-1 and clonidine were dissolved in sterile
Ringers injection solution. The intravenous injection volume
was 1 ml followed by a 400 µl flush of Ringers, whereas the
intracisternal injection volume was 25 µl followed by a 20 µl
flush.
Statistical Analysis
All values in the text are expressed as mean ± standard error
of the mean (SEM) or mean difference ± standard error of
the difference (SED) as appropriate. The pressor response to
intravenously administered endothelin-1 was analyzed with one-
way analysis of variance. The effect of clonidine in vehicle-
treated and endothelin-treated rabbits was combined in a single
repeated-measures two–factor analysis of variance where the
factors of “drug” and “animal” were removed from the total sums
of squares to give the residual sums of squares. The latter was
used to calculate the average “within animal” SEM (Snedecor and
Cochran, 1980). The effect of endothelin compared to vehicle
was determined by three sets of non-orthogonal contrasts. Thus,
the Bonferonni adjustment was made to correct for multiple
comparisons (Wallenstein et al., 1980).
RESULTS
Dose-Response Studies
Ganglionic blockade in conscious rabbits caused a moderate
fall in blood pressure (−11.7 ± 5.1 mmHg) and a tachycardia
(66 ± 10 b/min). The intravenous injection of endothelin-1
in ganglion-blocked rabbits caused an immediate and dose-
dependent decrease in blood pressure, rapidly followed by a long-
lasting pressor response (Figure 1). Injection of endothelin-1 at
the lowest dose of 50 ng/kg caused a small increase in MAP
of +3.0 ± 0.8 mmHg. At a dose of 200 ng/kg of endothelin-1,
the maximal change in blood pressure was +9.3 ± 2.9 mmHg,
whereas the highest dose of 1200 ng/kg of endothelin-1 increased
blood pressure by +33.0 ± 5.3 mmHg (Figure 1). In these
ganglion-blocked rabbits, there were very minimal effects of
endothelin-1 treatment on heart rate (not shown). Thus, there
was only a minimal pressor effect of the dose of 50 ng/kg,
which was subsequently used in our experiments to examine the
interaction of endothelin with the effects of clonidine.
Effect of Endothelin Treatment on the
Action of Clonidine
During the 3-week experimental period in which a total of 6
interaction experiments were performed, the average of body
weight, MAP and heart rate of these rabbits was 2.6 ± 0.1 kg,
74.5 ± 0.8 mmHg, and 153 ± 2 b/min, respectively. The rabbits
remained in good health and there were no significant changes to
any of these variables during this time. The final average value in
each case was within 4% of the initial value.
Intravenous administration of 50 ng/kg of endothelin-1 did
not significantly change MAP or heart rate from the initial
control value in these rabbits (0.0 ± 1.1 mmHg and +2.9 ±
4.5 b/min, respectively; Figure 2). However, the same dose given
intracisternally produced variable results. A large pressor (+26
mmHg at 30 min) and tachycardic response (+88 b/min) was
observed in one of the seven rabbits, a moderate increase in MAP
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FIGURE 1 | Change in mean arterial pressure (MAP) induced by the intravenous (iv) injection of endothelin-1. The top panel shows a typical trace of
pulsatile blood pressure, mean blood pressure, and heart rate of a conscious, ganglion blocked rabbit, before and after injection of 1200 ng/kg of endothelin-1 shown
at arrow. The bottom left panel shows individual maximal pressor responses of six conscious rabbits to doses of 50, 200, or 1200 ng/kg of endothelin-1, while the
bottom right panel shows the average responses of these animals.
and heart rate was observed in two other animals, but there was
little change in the other four animals. Thus, the overall average
change in MAP (+4.7 ± 4.4 mmHg) and heart rate (+18.9 ±
11.9 b/min) was not significant (Figure 2). The lower dose of
endothelin-1 (10 ng/kg) given intracisternally had no significant
effect on basal MAP and heart rate (+1.9 ± 0.9 mmHg and +6.6
± 4.1 b/min, respectively; Figures 2, 3).
Pretreatment with an intravenous or intracisternal injection
of Ringers solution (vehicle) prior to systemic administration
of clonidine had no effect on the basal MAP or heart rate
(Figures 2, 3).
The effect of intravenous treatment with clonidine on blood
pressure and heart rate in vehicle- or endothelin-1-pretreated
rabbits is shown in Figure 2 and in Table 1. In vehicle-pretreated
rabbits, intravenous injection of clonidine induced a decrease
in blood pressure and heart rate by −15.7 ± 4.7 mmHg and
−33 ± 4 b/min, respectively, at 15 min post-administration
(P < 0.02 and P < 0.001, respectively, n = 7). A similar
hypotension and bradycardia was induced by clonidine in rabbits
pretreated intravenously with 50 ng/kg of endothelin-1 (F1, 30
between groups = 0.5 and 0.7, respectively, P > 0.05). Similarly,
intracisternal pretreatment with 10 or 50 ng/kg of endothelin-
1 did not alter the responses to intravenously administered
clonidine (F1, 30 between groups = 0.1 and 0.3, respectively,
P > 0.05). Thus, none of the depressor or bradycardic responses
to clonidine administration following endothelin-1 pretreatment
were significantly different to those observed in the vehicle-
treated rabbits (Table 1).
The effect of intracisternal treatment with clonidine on blood
pressure and heart rate in rabbits which were centrally pretreated
with vehicle or endothelin-1 is shown in Figure 3. Intracisternal
injection of clonidine lowered blood pressure in vehicle-treated
rabbits by −16.0 ± 2.5 mmHg (P < 0.001), but produced a
less pronounced bradycardia when compared to intravenous
treatment (−18 ± 4 b/min, P < 0.005). Central pretreatment
with 10 ng/kg of endothelin-1 had no significant effect on
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FIGURE 2 | Mean arterial pressure (MAP) and heart rate (HR)
responses to intravenous (iv) injection of clonidine (20 µg/kg) over a 60
min time course following vehicle pretreatment (closed circles) or
pretreatment with endothelin–1: 50 ng/kg intravenously (squares), 10
ng/kg intracisternally (ic) (triangle up) or 50 ng/kg intracisternally
(triangle down). C1 indicates initial basal values and C2 indicates MAP and
heart rate 30 min after pretreatment injection. Error bars are ± 1 SEM from
analysis of variance and indicate variation between animals.
the hypotension or bradycardia produced by centrally injected
clonidine (Table 1, Figure 2, F1, 30 between groups= 0.3 and 3.6,
respectively, P > 0.05).
Effect of ET-1 Treatment on Baroreflex
Curves
The central injection of 10 ng/kg of endothelin-1 in this group
of conscious rabbits produced a prominent but short-lasting
pressor (15–20 mmHg) and tachycardic (30–40 b/min) response.
Furthermore, this dose of endothelin-1 produced a marked and
significant reduction of the baroreceptor reflex gain (−15.1± 2.2
vs. −9.9 ± 1.4 b/min/mmHg, P = 0.003), which was due to a
decrease in the curvature coefficient (Table 2). Neither heart rate
range nor any of the other baroreflex parameters were altered.
Central injection of vehicle did not affect basal MAP or heart rate.
In contrast, in these rabbits we observed a significant increase
in baroreflex gain (−11.0 ± 0.9 vs. −14.7 ± 2.3 b/min/mmHg),
which could indicate a time-related effect on reflex sensitivity
(Table 2). No other baroreflex parameters were altered by vehicle
FIGURE 3 | Mean arterial pressure (MAP) and heart rate (HR)
responses to intracisternal (ic) injection of clonidine (1 µg/kg) over a
60 min time course following intracisternal pretreatment with vehicle
(filled circle) or endothelin–1 (10 ng/kg, open triangle). C1 indicates initial
basal values and C2 indicates MAP and heart rate 30 min after pretreatment
injection. Error bars, as for Figure 1.
TABLE 1 | Changes in mean arterial pressure (MAP) and heart rate (HR)
induced 15 min following clonidine administration in vehicle or
endothelin-1-pretreated rabbits.
Pretreatment Dose Treatment Dose Change in Change in
(ng/kg) (µg/kg) MAP (mmHg) HR (b/min)
Vehicle ic/iv Clonidine iv 20 −15.7 ± 4.7 −33 ± 4
Endothelin-1 iv 50 Clonidine iv 20 −13.0 ± 1.2 −27 ± 6
Endothelin-1 ic 10 Clonidine iv 20 −16.2 ± 3.4 −34 ± 8
Endothelin-1 ic 50 Clonidine iv 20 −13.0 ± 2.3 −41 ± 8
Vehicle ic Clonidine ic 1 −16.0 ± 2.5 −18 ± 4
Endothelin-1 ic 10 Clonidine ic 1 −14.8 ± 2.0 −25 ± 4
Values are mean difference ± SED. ic, intracisternal; iv, intravenous.
treatment. The central injection of 2 ng/kg of endothelin-1 did
not cause any change in basal MAP, heart rate, heart rate range
or any of the other baroreflex parameters but tended to cause a
slight increase in baroreflex gain, similar to the effect seen after
vehicle treatment.
DISCUSSION
The present study demonstrates that intravenous injection of
endothelin-1 in conscious rabbits induces a dose-dependent
pressor response, similar to that described in rats and other
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TABLE 2 | Changes in barorflex paramaters before (control) and after administration of vehicle or endothelin −1.
Parameter Control Vehicle P Control ET1 2 ng/kg IC P Control ET1 10 ng/kg IC P
Resting MAP (mmHg) 87.6±1.6 84.3±1.4 0.15 91.6± 1.5 87.7±1.9 0.09 90.4± 2.9 90.9± 2.3 0.819
Resting HR (b/min) 187±4 186±4 0.82 200± 8 204±7 0.48 198± 9 205± 8 0.273
Lower plateau (b/min) 122±6 121±6 0.82 125± 7 125±8 0.96 125± 7 121± 7 0.543
Range (b/min) 202±14 205±15 0.86 213± 8 215±5 0.85 206± 12 220± 11 0.261
Upper plateau (b/min) 308±14 309±13 0.95 338± 3 340±10 0.86 330± 10 340± 9 0.385
Curvature 0.26±0.03 0.35±0.07 0.06 0.25± 0.03 0.29±0.03 0.38 0.35± 0.06 0.21± 0.04 0.006
BP50 (mmHg) 84.7±1 82±1.2 0.17 88.7± 1.5 85.6±2.2 0.12 87.7± 2.6 88.1± 2.1 0.830
GAIN (b/min/mmHg) −11± −1 −14.7±−2.3 0.03 −11.6±−1.5 −13.6±1.3 0.22 −15.1± 2.2 −9.9±−1.4 0.003
n 6 5 6
species (Yanagisawa et al., 1988; Sokolovsky, 1992; Huggins
et al., 1993). At doses that caused minimal vasoconstrictor
effects or changes in blood pressure, neither systemic nor central
pretreatment with endothelin–1 caused any significant effect
on the cardiovascular responses to systemically or centrally
administered clonidine in conscious rabbits. The doses of
endothelin we used were the maximum that could be used to
investigate a specific, pharmacological antagonism. Our results
do not support the view expressed in the studies of Gulati (1992)
and Gulati and Srimal (1993) that there is a central and peripheral
interaction between the effects of clonidine and endothelin. It
was suggested by these authors that endothelin antagonized the
clonidine-induced hypotension and bradycardia but potentiated
the initial hypertensive response induced by intravenously
administered clonidine. This effect was longlasting, since the
hypotension and bradycardia produced by clonidine were still
attenuated 4 h after treatment with endothelin-1 (Gulati, 1992).
Furthermore, after intracerebroventricular injection or topical
application on the ventral surface of the medulla oblongata,
endothelin-1 caused a retardation of the effects of similarly
administered clonidine (Gulati, 1992; Gulati and Srimal, 1993).
It is worth noting that the intracerebroventricular injection
of angiotensin-II also caused a complete inhibition of the
hypotension and bradycardia induced by either intravenous
or intracerebroventricular injection of clonidine (Gulati and
Srimal, 1993). This would indicate that this is not a specific
interaction and can occur with other, non-endothelin peptides.
The interaction between clonidine and endothelin was also
examined by Lim et al. using urethane anaesthetized rabbits
where they found that pretreatment increased the hypotension
when given intravenously but not when given intracisternally.
However, the basal pressures were not given but sample traces
suggest that MAP was 130 mmHg which is twice that of a normal
conscious rabbit (Lim et al., 1998).
It is well-established that the biphasic response to clonidine
involves both peripheral and central α-adrenoceptors. The initial
rise in pressure is due to the excitation of peripheral receptors
while the dominating hypotensive action of clonidine is due to
a central mechanism in which central α-adrenoceptors play an
important role (Kobinger, 1978; Van Zwieten and Timmermans,
1979). There is evidence to suggest that endothelins may
modulate systemic α-adrenoceptor-mediated sympathetic
nervous system responses (Wiklund et al., 1989; Tabuchi et al.,
1990; Ieda et al., 2004) and also central catecholamine release
(Koizumi et al., 1992). In the former studies, the addition of
endothelins reduced noradrenaline release from sympathetic
nerve endings, but enhanced postjunctional α-adrenoceptor
responses. Gulati (1992) concluded that, considering the
differential effect of endothelins on the cardiovascular responses
to clonidine, systemic and central α2-adrenoceptors involved in
the action of clonidine are different. It is important to note that
it was suggested that endothelin-1 would cross the blood-brain
barrier in order to exert its effect on central α2-adrenoceptors.
Such a mechanism is difficult to accept as Koseki et al. (1989)
failed to find any central labeling after the systemic injection
of radiolabelled endothelin and suggested that little, if any,
endothelin could enter the brain from the systemic circulation.
It cannot be excluded, however, that systemic endothelins affect
central mechanisms through an action on circumventricular
organs. Indeed, in regions such as the area postrema and
subfornical organ, intravenous injection of low doses of
endothelin caused cellular excitation (Ferguson and Smith,
1991; Wall et al., 1992). It should be stressed that the primary
site of action of clonidine on blood pressure, heart rate, and
sympathetic nervous system activity appears to be in the rostral
ventrolateral medulla (Punnen et al., 1987; Gatti et al., 1988).
The presence of endothelin receptors has been demonstrated in
the ventrolateral medulla (Kohzuki et al., 1991; van den Buuse
and Itoh, 1993) and, while intravenously injected endothelin
is not likely to reach this site, intracerebroventricular (Gulati
and Srimal, 1993) or intracisternal injection (present study) of
endothelin-1 would be able to reach the ventrolateral medulla.
However, we found no evidence of an interaction of endothelin
with clonidine.
It is possible that the interaction between endothelin
and clonidine observed by Gulati and colleague is a
functional antagonism rather than a pharmacological
interaction. Endothelin-1 has been established as a very
potent vasoconstrictor (Yanagisawa et al., 1988; Huggins et al.,
1993). However, when administered at low to moderate doses,
endothelin does not cause changes in blood pressure because
the increase in vascular tone is masked by a baroreflex-mediated
reduction of sympathetic vasomotor tone. In this case the
normal sympathoinhibition produced by clonidine would not
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be observed and a physiological antagonism has occurred.
This mechanism would not, however, explain the blockade
of bradycardia by endothelin. The bradycardia induced by
clonidine is due to cardiac sympathetic inhibition as well as
increased vagal tone due to a facilitation of the vagal component
of the baroreceptor-heart rate reflex (Badoer et al., 1983). One
possibility is that the normal resetting of the baroreceptor-
heart rate reflex, that permits the bradycardia to occur in
the presence of a fall in blood pressure, has not taken place.
Intracisternal administration of endothelin-1 produces a
facilitation of the vagal component of the baroreceptor-heart
rate reflex in conscious normotensive and hypertensive rats
(Itoh and van den Buuse, 1991; van den Buuse and Itoh,
1993). However, in the present study we demonstrated a
reduction of the gain of the baroreceptor-heart rate reflex
produced by intracisternal endothelin-1 (Figure 4). This
illustrates that there could be important species differences
between rabbits and rats. Indeed, this also applies to the
effects of clonidine. One of the most obvious differences is
the relative lack of a pressor effect of intravenously injected
clonidine in conscious rabbits. In rabbits, the pressor response
is very transient and maximal at usually around 30 s after
injection. The preponderance of the central depressor effect
FIGURE 4 | Average HR baroreflex curves (left panels) from control
(dotted line), ET-1 treated rabbits (2 ng/kg and 10 ng/kg, solid line) and
histograms (right panels) for baroreflex gain (b/min/mmHg) from
control (open bars) and ET-1 treated rabbits (2 ng/kg and 10 ng/kg,
filled bars). Resting points are indicated by open circle (control) or square
symbols (Et-1 Treated). Error bars are SEM, indicating variation between
animals. *P < 0.05.
soon takes over and by 5 min after injection it is close to its
maximum (Figure 2). By contrast, in rats the hypertensive
effect following systemic injection of clonidine is much more
prolonged. A further difference is that in rats there appears to
be a pronounced central pressor action of clonidine, which is
not observed in rabbits (Head and de Jong, 1986; Kawasaki et al.,
1992).
Whatever the mechanism behind the possible interaction of
endothelin-1 and clonidine in the studies from Gulati (1992),
Gulati and Srimal (1993), and Lavhale et al. (2010), we failed
to find any significant effect of pretreatment with endothelin-
1 on the hypotensive and bradycardic action of clonidine in
conscious rabbits. The dose of endothelin-1 and the pretreatment
time which we used in our studies were similar to those used
in the rat studies. Higher central doses of endothelin were not
used in our study, as they may induce systemic or cerebral
vasoconstriction and ischaemia, which could lead to direct or
reflex increases in blood pressure, respectively (Macrae et al.,
1991; van den Buuse, 1997). Indeed, higher doses of systemically
injected endothelin-1 caused a pronounced rise in blood pressure
in the present experiments. Moreover, the intracisternal injection
of 50 ng/kg, but not 10 ng/kg, in the present experiments
produced hypertension in one rabbit and a moderate increase in
blood pressure in two others, suggesting that this dose was at the
pressor threshold.
In our experiments we used conscious rabbits, while urethane-
anaesthetized rats were used in the previous studies. In rabbits
the doses of clonidine are close to the maximal doses for
intravenous and intracisternal routes of administration and
represent appropriate doses for the examination of an interaction
with endothelin (Head et al., 1983). Conscious animals are
preferable over anaesthetized animals as anaesthesia may alter
cardiovascular reflexes and centrally-mediated responses and
may affect pharmacokinetics of injected drugs, such that they are
cleared or metabolized at a different rate. It cannot be excluded
that the results obtained by Gulati (1992), Gulati and Srimal
(1993) and Lavhale et al. (2010) can only be reproduced in
anaesthetized animals.
In conclusion, endothelin-1 is an effective pressor agent
in conscious rabbits. However, while previous studies in
anaesthetized rats have shown that endothelins may interact with
the central antihypertensive action of clonidine, at subpressor
doses of endothelin we did not find evidence for such an
interaction in conscious rabbits.
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